HEPA — Hepion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Hepion Pharmaceuticals To Present Data On Synergistic Effects Of Rencofilstat With Anti-Pd1 At Aacr 2023
Brief: Epo Decision To Grant European Patent For Rencofilstat Further Strengthens Hepion’s Patent Portfolio
Brief: Anti-Cancer Potential Of Rencofilstat Expanded With Results From Preclinical Multiple Myeloma Studies
U.S. STOCKS ON THE MOVE-Bed Bath and Beyond, gold miners, WWE
Brief: Hepion Pharmaceuticals Receives $3.2 Million In Aggregate Non-Dilutive Funding
Brief: Hepion Pharmaceuticals Inc Says It Has Been Granted 180-Day Extension By Nasdaq To Meet The Minimum Bid Price Requirements
Hepion rises after completing enrollment in NASH drug trial
Brief: Hepion Pharmaceuticals Announces Early Completion Of Enrollment In Phase 2 ‘Altitude-Nash’ Liver Function Trial
Brief: Hepion Pharmaceuticals Announces Publication Of Phase 2A ‘Ambition’ Clinical Trial Results
Brief: Hepion Announces Initiation Of Dosing In Phase 2 'Altitude-Nash' Liver Function Trial
U.S. STOCKS ON THE MOVE-Guardant Health, PayPal, Bausch Health
U.S. STOCKS ON THE MOVE-Moderna, Addentax, Baxter
U.S. STOCKS ON THE MOVE-Chico's FAS, Nuwellis, Toyota
Hepion Pharma edges up on starting liver disease treatment trial
Brief: Hepion Begins Phase 2B ‘Ascend-Nash’ Trial
Brief: Hepion Pharmaceuticals Announces Further Adjournment Of Annual Meeting Of Stockholders
Brief: Hepion Pharmaceuticals Inc Says Board Increased Size Of Board To Eight Members
Brief: Hepion Pharmaceuticals Further Strengthens Board With Appointments Of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi And Dr. Kaouthar Lbiati
Brief: Hepion Pharmaceuticals Announces Adjournment Of Annual Meeting Of Stockholders